Comprehensive Stock Comparison
Compare DaVita Inc. (DVA) vs Concord Medical Services Holdings Limited (CCM) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | DVA | 6.5% revenue growth vs CCM's -28.6% |
| Value | CCM | Lower P/E (0.9x vs 11.0x) |
| Quality / Margins | DVA | 5.5% net margin vs CCM's -44.6% |
| Stability / Safety | CCM | Beta 0.25 vs DVA's 0.35, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | DVA | +5.7% vs CCM's -29.9% |
| Efficiency (ROA) | DVA | 4.3% ROA vs CCM's -2.4%, ROIC 10.5% vs -7.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
DaVita is a leading provider of kidney dialysis services for patients with chronic kidney failure. It generates revenue primarily from operating outpatient dialysis centers — which provide the bulk of its income — along with related lab services, home-based dialysis, and integrated care arrangements. The company's scale and network of over 2,800 U.S. centers create significant barriers to entry and operational efficiencies in a capital-intensive, regulated healthcare segment.
Concord Medical Services operates a network of radiotherapy and diagnostic imaging centers across China, specializing in cancer treatment services. It generates revenue primarily from operating its network of treatment centers — including linear accelerators and gamma knife systems — and from hospital management services, with additional income from equipment leasing and medical IT services. The company's competitive advantage lies in its established network of specialized cancer treatment facilities across China and its expertise in advanced radiotherapy technologies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
DVA leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). CCM leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
DVA is the larger business by revenue, generating $13.6B annually — 37.3x CCM's $366M. DVA is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to CCM's -44.6%. On growth, DVA holds the edge at +9.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DVADaVita Inc. | CCMConcord Medical S… |
|---|---|---|
| RevenueTrailing 12 months | $13.6B | $366M |
| EBITDAEarnings before interest/tax | $2.7B | -$359M |
| Net IncomeAfter-tax profit | $747M | -$163M |
| Free Cash FlowCash after capex | $1.3B | $0 |
| Gross MarginGross profit ÷ Revenue | +30.9% | -11.4% |
| Operating MarginEBIT ÷ Revenue | +14.9% | -131.0% |
| Net MarginNet income ÷ Revenue | +5.5% | -44.6% |
| FCF MarginFCF ÷ Revenue | +9.6% | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.9% | -8.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.7% | +84.0% |
Valuation Metrics
| Metric | DVADaVita Inc. | CCMConcord Medical S… |
|---|---|---|
| Market CapShares × price | $10.4B | $167M |
| Enterprise ValueMkt cap + debt − cash | $24.7B | $708M |
| Trailing P/EPrice ÷ TTM EPS | 17.23x | -0.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.02x | 0.87x |
| PEG RatioP/E ÷ EPS growth rate | 2.38x | — |
| EV / EBITDAEnterprise value multiple | 9.08x | — |
| Price / SalesMarket cap ÷ Revenue | 0.77x | 2.98x |
| Price / BookPrice ÷ Book value/share | 11.89x | 0.00x |
| Price / FCFMarket cap ÷ FCF | 7.97x | — |
Profitability & Efficiency
DVA delivers a 64.5% return on equity — every $100 of shareholder capital generates $64 in annual profit, vs $-9 for CCM. CCM carries lower financial leverage with a 2.43x debt-to-equity ratio, signaling a more conservative balance sheet compared to DVA's 12.99x. On the Piotroski fundamental quality scale (0–9), DVA scores 5/9 vs CCM's 3/9, reflecting solid financial health.
| Metric | DVADaVita Inc. | CCMConcord Medical S… |
|---|---|---|
| ROE (TTM)Return on equity | +64.5% | -9.5% |
| ROA (TTM)Return on assets | +4.3% | -2.4% |
| ROICReturn on invested capital | +10.5% | -7.7% |
| ROCEReturn on capital employed | +14.0% | -12.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 12.99x | 2.43x |
| Net DebtTotal debt minus cash | $14.3B | $3.7B |
| Cash & Equiv.Liquid assets | $758M | $216M |
| Total DebtShort + long-term debt | $15.0B | $3.9B |
| Interest CoverageEBIT ÷ Interest expense | 3.51x | -2.40x |
Total Returns (with DRIP)
A $10,000 investment in DVA five years ago would be worth $15,197 today (with dividends reinvested), compared to $992 for CCM. Over the past 12 months, DVA leads with a +5.7% total return vs CCM's -29.9%. The 3-year compound annual growth rate (CAGR) favors DVA at 23.9% vs CCM's -36.5% — a key indicator of consistent wealth creation.
| Metric | DVADaVita Inc. | CCMConcord Medical S… |
|---|---|---|
| YTD ReturnYear-to-date | +36.5% | -14.8% |
| 1-Year ReturnPast 12 months | +5.7% | -29.9% |
| 3-Year ReturnCumulative with dividends | +90.0% | -74.4% |
| 5-Year ReturnCumulative with dividends | +52.0% | -90.1% |
| 10-Year ReturnCumulative with dividends | +136.9% | -92.1% |
| CAGR (3Y)Annualised 3-year return | +23.9% | -36.5% |
Risk & Volatility
CCM is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than DVA's 0.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DVA currently trades 99.0% from its 52-week high vs CCM's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DVADaVita Inc. | CCMConcord Medical S… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.35x | 0.25x |
| 52-Week HighHighest price in past year | $157.91 | $10.77 |
| 52-Week LowLowest price in past year | $101.00 | $3.18 |
| % of 52W HighCurrent price vs 52-week peak | +99.0% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 71.1 | 41.9 |
| Avg Volume (50D)Average daily shares traded | 961K | 7K |
Analyst Outlook
Wall Street rates DVA as "Hold" and CCM as "Buy".
| Metric | DVADaVita Inc. | CCMConcord Medical S… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $168.67 | — |
| # AnalystsCovering analysts | 23 | 2 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 3 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +17.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| DaVita Inc. (DVA) | 100 | 135.22 | +35.2% |
| Concord Medical Ser… (CCM) | 100 | 16.67 | -83.3% |
DaVita Inc. (DVA) returned +52% over 5 years vs Concord Medical Ser… (CCM)'s -90%. A $10,000 investment in DVA 5 years ago would be worth $15,197 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DaVita Inc. (DVA) | $14.7B | $13.6B | -7.5% |
| Concord Medical Ser… (CCM) | $455M | $384M | -15.6% |
DaVita Inc.'s revenue grew from $14.7B (2016) to $13.6B (2025) — a -0.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DaVita Inc. (DVA) | 6.0% | 5.5% | -8.3% |
| Concord Medical Ser… (CCM) | -57.5% | -80.3% | -39.5% |
DaVita Inc.'s net margin went from 6% (2016) to 5% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| DaVita Inc. (DVA) | 20.8 | 12.5 | -39.9% |
DaVita Inc. has traded in a 11x–21x P/E range over 9 years; current trailing P/E is ~17x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DaVita Inc. (DVA) | 4.29 | 9.07 | +111.4% |
| Concord Medical Ser… (CCM) | -1,804.2 | -2,116.8 | -17.3% |
DaVita Inc.'s EPS grew from $4.29 (2016) to $9.07 (2025) — a 9% CAGR.
Chart 6Free Cash Flow — 5 Years
DaVita Inc. generated $1B FCF in 2025 (+2% vs 2021). Concord Medical Services Holdings Limited generated $-809M FCF in 2024 (+28% vs 2021).
DVA vs CCM: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is DVA or CCM a better buy right now?
DaVita Inc. (DVA) offers the better valuation at 17.2x trailing P/E (11.0x forward), making it the more compelling value choice. Analysts rate Concord Medical Services Holdings Limited (CCM) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DVA or CCM?
On forward P/E, Concord Medical Services Holdings Limited is actually cheaper at 0.9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — DVA or CCM?
Over the past 5 years, DaVita Inc. (DVA) delivered a total return of +52.0%, compared to -90.1% for Concord Medical Services Holdings Limited (CCM). A $10,000 investment in DVA five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: DVA returned +136.9% versus CCM's -92.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DVA or CCM?
By beta (market sensitivity over 5 years), Concord Medical Services Holdings Limited (CCM) is the lower-risk stock at 0.25β versus DaVita Inc.'s 0.35β — meaning DVA is approximately 39% more volatile than CCM relative to the S&P 500. On balance sheet safety, Concord Medical Services Holdings Limited (CCM) carries a lower debt/equity ratio of 2% versus 13% for DaVita Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — DVA or CCM?
DaVita Inc. (DVA) is the more profitable company, earning 5.5% net margin versus -80.3% for Concord Medical Services Holdings Limited — meaning it keeps 5.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DVA leads at 14.7% versus -138.6% for CCM. At the gross margin level — before operating expenses — DVA leads at 27.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is DVA or CCM more undervalued right now?
On forward earnings alone, Concord Medical Services Holdings Limited (CCM) trades at 0.9x forward P/E versus 11.0x for DaVita Inc. — 10.1x cheaper on a one-year earnings basis.
07Which pays a better dividend — DVA or CCM?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is DVA or CCM better for a retirement portfolio?
For long-horizon retirement investors, DaVita Inc. (DVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.35), +136.9% 10Y return). Both have compounded well over 10 years (DVA: +136.9%, CCM: -92.1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between DVA and CCM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: DVA is a mid-cap deep-value stock; CCM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.